Literature DB >> 21770739

Clinical characteristics of keratitis due to Colletotrichum gloeosporioides.

Atsushi Shiraishi1, Kaoru Araki-Sasaki, Arisa Mitani, Hitoshi Miyamoto, Atsuko Sunada, Akiko Ueda, Seishi Asari, Xiaodong Zheng, Yasuaki Yamamoto, Yuko Hara, Yuichi Ohashi.   

Abstract

PURPOSE: To determine the characteristics of the keratitis due to Colletotrichum gloeosporioides.
METHODS: The medical records of 3 cases of fungal keratitis caused by C. gloeosporioides were reviewed to determine the clinical characteristics. The minimal inhibitory concentrations of different antifungal drugs for all 3 isolates were determined. All 3 isolates were grown on Sabouraud dextrose agar at 25°C, 35°C, and 37°C to determine the temperature-sensitive growth.
RESULTS: All 3 patients lived in the southwestern part of Japan and had an ocular trauma involving organic materials. The infectious foci were localized in the anterior stroma, and they did not extend deep into the stroma in all cases. The keratitis was treated with antifungal medications including topical voriconazole and natamycin eye ointment, and was resolved in 2-3 weeks. All of the isolated strains grew well at 25°C but poorly at 35°C and 37°C. All isolated strains had similar drug-sensitivity profiles; they were sensitive to amphotericin B, itraconazole, miconazole, micafungin, and voriconazole, and relatively resistant to flucytosine, fluconazole, and natamycin.
CONCLUSIONS: All 3 cases of C. gloeosporioides keratitis had similar clinical features. The similarities in the drug-sensitivity profiles should be helpful in treating C. gloeosporioides keratitis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21770739     DOI: 10.1089/jop.2011.0011

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  8 in total

1.  Coelomycetous Fungi in the Clinical Setting: Morphological Convergence and Cryptic Diversity.

Authors:  Nicomedes Valenzuela-Lopez; Deanna A Sutton; José F Cano-Lira; Katihuska Paredes; Nathan Wiederhold; Josep Guarro; Alberto M Stchigel
Journal:  J Clin Microbiol       Date:  2016-12-07       Impact factor: 5.948

2.  Updating species diversity of Colletotrichum, with a phylogenomic overview.

Authors:  F Liu; Z Y Ma; L W Hou; Y Z Diao; W P Wu; U Damm; S Song; L Cai
Journal:  Stud Mycol       Date:  2022-01-11       Impact factor: 25.731

3.  Therapeutic Penetrating Keratoplasty in a Case of Corneal Perforation Caused by Colletotrichum gloeosporioides Infection.

Authors:  Kazuki Imai; Takayoshi Sumioka; Hiroki Iwanishi; Yukihisa Takada; Shin'ichi Murata; Ryuta Iwamoto; Yuka Okada; Shizuya Saika
Journal:  Pathogens       Date:  2022-04-29

4.  Colletotrichum - current status and future directions.

Authors:  P F Cannon; U Damm; P R Johnston; B S Weir
Journal:  Stud Mycol       Date:  2012-09-15       Impact factor: 16.097

5.  Colletotrichum truncatum species complex: Treatment considerations and review of the literature for an unusual pathogen causing fungal keratitis and endophthalmitis.

Authors:  Victoria Squissato; Yeni H Yucel; Susan E Richardson; Alaa Alkhotani; David T Wong; Navdeep Nijhawan; Clara C Chan
Journal:  Med Mycol Case Rep       Date:  2015-06-05

6.  Fungal keratitis caused by Beauveria bassiana: drug and temperature sensitivity profiles: a case report.

Authors:  Arisa Mitani; Atsushi Shiraishi; Hitoshi Miyamoto; Atsuko Sunada; Akiko Ueda; Seishi Asari; Xiaodong Zheng; Yasuaki Yamamoto; Yuko Hara; Yuichi Ohashi
Journal:  BMC Res Notes       Date:  2014-09-27

7.  Non-traumatic keratitis due to Colletotrichum truncatum.

Authors:  Reina Llamos; Abdullah M S Al-Hatmi; Gerardo Martínez; Ferry Hagen; Rosario Velar; Alexeide de la Caridad Castillo Pérez; Jacques F Meis; María T Illnait-Zaragozí
Journal:  JMM Case Rep       Date:  2016-08-30

8.  [Fungal keratitis caused by Colletotrichum gloeosporioides: A case report].

Authors:  I Zakariya-Yousef Breval; A Márquez Sanabria; A Guzmán González; A Tenorio Abreu
Journal:  Rev Esp Quimioter       Date:  2019-03-06       Impact factor: 1.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.